BillionToOne, Inc. (BLLN) Stock Analysis
Healthcare · Diagnostics & Research
Hold if already holding. Not a fresh buy at $101.60, but acceptable to hold if already in. Reasons: Concentration risk — Customer: third-party payors; Analyst target reached - limited upside remaining.
BillionToOne develops molecular diagnostic tests using its single-molecule sequencing platform, commercializing the UNITY prenatal test portfolio (launched 2019) and Northstar oncology tests for therapy selection and response monitoring (launched 2023). Third-party... Read more
Hold if already holding. Not a fresh buy at $101.60, but acceptable to hold if already in. Reasons: Concentration risk — Customer: third-party payors; Analyst target reached - limited upside remaining. Chart setup: No clear chart pattern; technical signals are mixed. Maintain position. Not compelling to add more. Score 5.8/10, moderate confidence.
Passes 7/8 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, earnings proximity 50d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: aggressive.
About BillionToOne, Inc.
About BillionToOne, Inc.
BillionToOne launched UNITY Fetal Risk Screen in 2019—the first NIPT to assess fetal risk for recessive conditions such as sickle cell disease and cystic fibrosis from a maternal blood draw without requiring a paternal sample—and entered oncology in January 2023 with Northstar Select, an ultrasensitive liquid biopsy for stage III/IV cancer therapy selection. Third-party payors represented more than 90% of the company's revenue in 2025 and 2024. The company was founded in 2016 and received its first commercial test sample in 2019.
BillionToOne earns revenue when third-party payors reimburse for molecular diagnostic tests ordered by obstetricians and oncologists. The UNITY prenatal portfolio covers recessive conditions, chromosomal aneuploidies, 22q11.2 microdeletion, fetal RhD status, and red blood cell antigens; UNITY Fetal Antigen NIPT is described as the only commercially available test for fetal antigen screening in the United States. The Northstar oncology portfolio includes Northstar Select for therapy selection and Northstar Response for methylation-based tumor burden monitoring; more than 95% of oncologists ordering the company's tests in 2025 used both products in tandem. Reimbursement coverage is uneven: Northstar Select is broadly covered by Medicare but narrowly by commercial insurers (limited to specific indications such as lung cancer), while Northstar Response is covered by neither Medicare nor most commercial insurers. Prenatal tests are processed at a Union City laboratory enrolled as a Medicaid provider in over 40 states.
Show full overview
The Centers for Medicare & Medicaid Services (CMS) sets reimbursement rates annually through the Clinical Laboratory Fee Schedule (CLFS); PAMA-driven rate reductions—suspended since 2021 but the company notes the reporting requirement has been delayed most recently until 2026—may reduce Medicare reimbursement when eventually implemented. Because many commercial insurers and state Medicaid plans set rates as a percentage of Medicare CLFS amounts, a CMS rate cut would have cascading effects across payors. Approximately half of all U.S. births involve Medicaid beneficiaries, making state Medicaid coverage decisions particularly load-bearing for the prenatal franchise revenue base.
See also: Healthcare · Diagnostics & Research
From BillionToOne, Inc.'s most recent 10-K filing, extracted June 9, 2026.
Recent developments
updated 2026-06-17Recent Developments — BillionToOne, Inc.
Latest news
- NEWS BillionToOne (NASDAQ:BLLN) Momentum Fuels Nasdaq Healthcare Interest - Kalkine Media — Kalkine Media positive
- NEWS Solid Earnings Reflect BillionToOne's (NASDAQ:BLLN) Strength As A Business - Yahoo Finance — Yahoo Finance positive
- NEWS Guggenheim raises BillionToOne stock price target to $120 on reimbursement progress - Investing.com UK — Investing.com UK positive
- NEWS Guggenheim raises BillionToOne stock price target to $120 on reimbursement progress - Investing.com — Investing.com positive
- NEWS BillionToOne (BLLN) Reports Q1 Earnings: What Key Metrics Have to Say - Yahoo Finance — Yahoo Finance neutral
Generated 2026-06-17T09:02:25Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHCustomerthird-party payors10-K Item 1A: 'Reimbursement from third-party payors for our tests represented more than 90% of our revenue for each of the years ended December 31, 2025 and 2024'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers·1 ceiling hit
Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $101.60, but acceptable to hold if already in. Reasons: Concentration risk — Customer: third-party payors; Analyst target reached - limited upside remaining. Chart setup: No clear chart pattern; technical signals are mixed. Maintain position. Not compelling to add more. Target $102.41 (+0.8%), stop $93.65 (−8.5%), A.R:R 0.1:1. Score 5.8/10, moderate confidence.
Take-profit target: $102.41 (+1.7% upside). Target $102.41 (+0.8%), stop $93.65 (−8.5%), A.R:R 0.1:1. Stop-loss: $93.65.
Concentration risk — Customer: third-party payors; Analyst target reached - limited upside remaining; Expensive valuation.
BillionToOne, Inc. trades at a P/E of 192.5 (forward 100.9). TrendMatrix value score: 2.7/10. Verdict: Hold.
14 analysts cover BLLN with a consensus score of 4.2/5. Average price target: $118.
What does BillionToOne, Inc. do?BillionToOne develops molecular diagnostic tests using its single-molecule sequencing platform, commercializing the...
BillionToOne develops molecular diagnostic tests using its single-molecule sequencing platform, commercializing the UNITY prenatal test portfolio (launched 2019) and Northstar oncology tests for therapy selection and response monitoring (launched 2023). Third-party payors—including Medicare, Medicaid, and commercial insurers—represented more than 90% of revenue in 2025 and 2024. The company describes UNITY Fetal Antigen NIPT as the only commercially available test for fetal antigen screening in the United States.